Joakim Wijkstrom
Net Worth
Last updated:
What is Joakim Wijkstrom net worth?
The estimated net worth of Mr. Joakim Wijkstrom is at least $4,862,729 as of 5 Mar 2024. He owns shares worth $591,838 as insider, has earned $339,041 from insider trading and has received compensation worth at least $3,931,850 in Vanda Pharmaceuticals Inc..
What is the salary of Joakim Wijkstrom?
Mr. Joakim Wijkstrom salary is $786,370 per year as Senior Vice President & Chief Marketing Officer in Vanda Pharmaceuticals Inc..
How old is Joakim Wijkstrom?
Mr. Joakim Wijkstrom is 59 years old, born in 1966.
What stocks does Joakim Wijkstrom currently own?
As insider, Mr. Joakim Wijkstrom owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | Senior Vice President & Chief Marketing Officer | 129,789 | $4.56 | $591,838 |
What does Vanda Pharmaceuticals Inc. do?
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Joakim Wijkstrom insider trading
Vanda Pharmaceuticals Inc.
Mr. Joakim Wijkstrom has made 10 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 9,229 units of VNDA stock worth $38,826 on 5 Mar 2024.
The largest trade he's ever made was exercising 9,229 units of VNDA stock on 5 Mar 2024. As of 5 Mar 2024 he still owns at least 129,789 units of VNDA stock.
Vanda Pharmaceuticals key executives
Vanda Pharmaceuticals Inc. executives and other stock owners filed with the SEC:
- Dr. Mihael H. Polymeropoulos (65) Founder, Pres, Chief Executive Officer & Director
- Mr. Joakim Wijkstrom (59) Senior Vice President & Chief Marketing Officer
- Mr. Kevin Patrick Moran (41) Senior Vice President, Chief Financial Officer & Treasurer
- Mr. Timothy Williams (49) Senior Vice President, Gen. Counsel & Sec.